Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.

Autor: Heeres J; Center for Molecular Design, Janssen Pharmaceutica, Antwerpsesteenweg 37, B-2350 Vosselaar, Belgium. jheeres@prdbe.jnj.com, de Jonge MR, Koymans LM, Daeyaert FF, Vinkers M, Van Aken KJ, Arnold E, Das K, Kilonda A, Hoornaert GJ, Compernolle F, Cegla M, Azzam RA, Andries K, de Béthune MP, Azijn H, Pauwels R, Lewi PJ, Janssen PA
Jazyk: angličtina
Zdroj: Journal of medicinal chemistry [J Med Chem] 2005 Mar 24; Vol. 48 (6), pp. 1910-8.
DOI: 10.1021/jm040829e
Abstrakt: A series of novel pyrazinones designed as non-nucleoside reverse transcriptase inhibitors (NNRTIs) was synthesized and their anti-HIV structure-activity relationship (SAR) was studied.
Databáze: MEDLINE